B
Bellen
A Chinese medical contract research organization
About Bellen
Bellen Chemistry is a leading integrated Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in innovative chemistry solutions. Established in 2007, the company operates in the pharmaceutical sector, providing comprehensive services from discovery and development to manufacturing. Bellen Chemistry serves a global clientele, including pharmaceutical companies, biotech firms, and research institutions. The company operates multiple state-of-the-art facilities, including the Beijing Innovation Center, Shanghai Process R&D Center, and Shandong Manufacturing Plant, ensuring high-quality and scalable solutions. Bellen Chemistry's business model revolves around offering tailored chemistry services that meet the specific needs of its clients, thereby generating revenue through service contracts and long-term partnerships. The company is committed to continuous investment in its facilities and capabilities to better serve its worldwide clients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Shunyi District, China
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 68.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Chemistry, Product Research, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Bellen.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Jul 2020 | $28M | $110M | Huagai Capital · Eastern Bell Venture Capital · Insight Capital · Legend Capital | — |
| SERIES COther financing | Sep 2018 | $30M | $120M | Apricot Capital | — |
Growth signals
Latest recorded traffic for Bellen is 910 monthly website visits, up 225% over the last three months. Bellen's team declined 4.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
THG Ventures
Legend Capital
Series B and later4 investors entered at this stage
Apricot Capital
Huagai Capital
Eastern Bell Venture Capital- ICInsight Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bellen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bellen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.